» Articles » PMID: 14656202

Growth Hormone Therapy and Quality of Life: Possibilities, Pitfalls and Mechanisms

Overview
Journal J Endocrinol
Specialty Endocrinology
Date 2003 Dec 6
PMID 14656202
Citations 13
Authors
Affiliations
Soon will be listed here.
Abstract

The actions of growth hormone (GH) are not restricted to growth: GH modulates metabolic pathways as well as neural, reproductive, immune, cardiovascular, and pulmonary physiology. The importance of GH in most physiological systems suggests that GH deficiency at any age would be associated with significant morbidity. However, prior to the advent of recombinant GH, cadaver-derived GH was only used therapeutically to correct the height deficit, and thereby hypothetically improve quality of life (QoL), in GH-deficient children. Physicians now have access to unlimited, albeit expensive, supplies of recombinant GH, and are considering the advisability of GH replacement or supplementation in other patient populations. This paper analyses studies investigating the relationship between GH and QoL in GH-deficient children or adults, in GH-replete short children suffering from idiopathic short stature, Turner syndrome, or intrauterine growth retardation and in GH-deficient or replete elderly adults. Possible mechanisms by which GH might improve QoL at neural and somatic sites are also proposed.

Citing Articles

Retinal and choroidal microvascular assessment of children receiving recombinant growth hormone therapy : Study design: a prospective observational comparative study.

Omar I, Fadle Y, El Bakry N Int J Retina Vitreous. 2024; 10(1):90.

PMID: 39578934 PMC: 11583502. DOI: 10.1186/s40942-024-00610-z.


Adult height and health-related quality of life in patients born small for gestational age treated with recombinant growth hormone.

Rodrigez J, Toda L, Diez Lopez I, Munoz J, Fresno L, Hernandez E Sci Rep. 2023; 13(1):3135.

PMID: 36823445 PMC: 9950462. DOI: 10.1038/s41598-023-30281-z.


Regenerative Effect of Growth Hormone (GH) in the Retina after Kainic Acid Excitotoxic Damage.

Martinez-Moreno C, Epardo D, Balderas-Marquez J, Fleming T, Carranza M, Luna M Int J Mol Sci. 2019; 20(18).

PMID: 31509934 PMC: 6770150. DOI: 10.3390/ijms20184433.


Design of the Growth hormone deficiency and Efficacy of Treatment (GET) score and non-interventional proof of concept study.

Kann P, Bergmann S, Bidlingmaier M, Dimopoulou C, Pedersen B, Stalla G BMC Endocr Disord. 2018; 18(1):10.

PMID: 29433573 PMC: 5810096. DOI: 10.1186/s12902-018-0237-3.


On the role of skin in the regulation of local and systemic steroidogenic activities.

Slominski A, Manna P, Tuckey R Steroids. 2015; 103:72-88.

PMID: 25988614 PMC: 4631694. DOI: 10.1016/j.steroids.2015.04.006.